Open Access

Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia

  • Authors:
    • Yoshiko Azuma
    • Aya Nakaya
    • Masaaki Hotta
    • Shinya Fujita
    • Yukie Tsubokura
    • Hideaki Yoshimura
    • Atsushi Satake
    • Kazuyoshi Ishii
    • Tomoki Ito
    • Shosaku Nomura
  • View Affiliations

  • Published online on: April 20, 2016     https://doi.org/10.3892/mco.2016.864
  • Pages: 31-34
  • Copyright: © Azuma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gemtuzumab ozogamicin (GO) is a recombinant humanized immunoglobulin G4 anti-cluster of differentiation (CD)33 monoclonal antibody conjugated to N‑acetyl‑γ calicheamicin dimethylhydrazide, a naturally potent antibiotic. It has been introduced for the treatment of acute promyelocytic leukemia (APL), since large quantities of CD33 are commonly expressed on the surface of APL cells. The present study reported two cases with prominent disseminated intravascular coagulation (DIC), which was transiently observed following treatment with GO with relapsed/refractory APL. Very limited information exists regarding DIC occurring following GO, and its mechanism remains to be elucidated. In the present study, recombinant human soluble thrombomodulin was used for DIC treatment, and the patients recovered promptly. Since DIC is the most serious adverse event associated with GO treatment, elucidation of its mechanism and establishment of a treatment strategy are warranted.
View Figures
View References

Related Articles

Journal Cover

July 2016
Volume 5 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Azuma, Y., Nakaya, A., Hotta, M., Fujita, S., Tsubokura, Y., Yoshimura, H. ... Nomura, S. (2016). Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia. Molecular and Clinical Oncology, 5, 31-34. https://doi.org/10.3892/mco.2016.864
MLA
Azuma, Y., Nakaya, A., Hotta, M., Fujita, S., Tsubokura, Y., Yoshimura, H., Satake, A., Ishii, K., Ito, T., Nomura, S."Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia". Molecular and Clinical Oncology 5.1 (2016): 31-34.
Chicago
Azuma, Y., Nakaya, A., Hotta, M., Fujita, S., Tsubokura, Y., Yoshimura, H., Satake, A., Ishii, K., Ito, T., Nomura, S."Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia". Molecular and Clinical Oncology 5, no. 1 (2016): 31-34. https://doi.org/10.3892/mco.2016.864